Intradiscal rhGDF-5 Phase I/II Clinical Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Degenerative Disc Disease
Interventions
DRUG

Intradiscal rhGDF-5

The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.

Trial Locations (8)

23235

Virginia Commonwealth University Spine Center, Richmond

30060

Drug Studies America, Marietta

45242

Riverhills Healthcare, Inc., Cincinnati

60611

Rehabilitation Institute of Chicago, Chicago

75093

TBI Clinical Research, LLC, Plano

81301

Durango Orthopedic Associates/Spine Colorado, Durango

90404

Spine Institute, Santa Monica

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

DePuy Spine

INDUSTRY

NCT00813813 - Intradiscal rhGDF-5 Phase I/II Clinical Trial | Biotech Hunter | Biotech Hunter